Current situation and the latest progress in the treatment of pyoderma gangrenosum.
10.3760/cma.j.cn501225-20220330-00108
- Author:
Yang LI
1
;
Yuan Yuan WANG
1
;
Ke XING
1
;
Shan Shan LI
1
Author Information
1. Department of Dermatology, the First Hospital of Jilin University, Changchun 130021, China.
- Publication Type:Journal Article
- MeSH:
Biological Products;
Glucocorticoids;
Humans;
Immunosuppressive Agents;
Immunotherapy;
Interleukin Inhibitors;
Pyoderma Gangrenosum/drug therapy*
- From:
Chinese Journal of Burns
2022;38(6):574-579
- CountryChina
- Language:Chinese
-
Abstract:
Pyoderma gangrenosum (PG) is a rare chronic inflammatory non-infectious skin dermatosis, and there is no clear treatment guideline for this disease at home and abroad. There are a variety of clinical treatment methods for PG, including local therapy and systemic application of glucocorticoids, immunosuppressants, intravenous immuno- globulin, and biologics. Glucocorticoids are the first-line drugs commonly used in clinical practice, and immunosuppressants can be used alone or in combination with glucocorticoids. In recent years, more and more evidence has shown that biologics are a new trend in the treatment of PG, mainly including tumor necrosis factor α inhibitors, interleukin-1 (IL-1) inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, rituximab, and small molecular inhibitors. This article summarizes the current status and latest progress in the treatment of PG, hoping to provide clinicians with ideas for the treatment of PG.
